Synapse - Ellen Basu

Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression

Journal Article

Cheung, I. Y.; Cheung, N. K. V.; Modak, S.; Mauguen, A.; Feng, Y.; Basu, E.; Roberts, S. S.; Ragupathi, G.; Kushner, B. H.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Survival impact of anti-GD2 antibody response - A phase II ganglioside vaccine trial in relapsed neuroblastoma

Meeting Abstract

Cheung, I. Y.; Cheung, N. K. V.; Modak, S.; Mauguen, A.; Basu, E.; Roberts, S. S.; Ragupathi, G.; Kushner, B. H.
Cancer Research (2020)

Fulltext@MSK | Save

Entrectinib in recurrent or refractory solid tumors including primary CNS tumors: Updated data in children and adolescents

Meeting Abstract

Robinson, G.; Desai, A.; Basu, E.; Foster, J.; Gauvain, K.; Sabnis, A.; Shusterman, S.; Macy, M.; Mease, L.; Yoon, J.; more...
Neuro-Oncology (2020)

Fulltext@MSK | Save

Updated entrectinib data from a phase 1/2 trial in children and adolescents with recurrent or refractory solid tumors, including primary central nervous system (CNS) tumors

Meeting Abstract

Desai, A. V.; Robinson, G. W.; Basu, E. M.; Foster, J.; Gauvain, K.; Sabnis, A. J.; Macy, M. E.; Maese, L.; Yoon, J.; Cash, T.; more...
Pediatric Blood and Cancer (2020)

Fulltext@MSK | Save

High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial